Titre du document / Document title

A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients

Auteur(s) / Author(s)

DIAZ-MARTINEZ A. ⁽¹⁾ ; BENASSINNI O. ⁽²⁾ ; ONTIVEROS A. ⁽³⁾ ; GONZALEZ S. ⁽⁴⁾ ; SALIN R. ⁽⁵⁾ ; BASQUEDANO G. ⁽⁶⁾ ; MARTINEZ R. A. ⁽⁷⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Federacion Mexicana de Sociedades Pro-Salud Mental, Mexico City, MEXIQUE
⁽²⁾ Mental Health Service, State of Sonora, Hermosillo, Sonora, MEXIQUE
⁽³⁾ Psychiatry Department, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, MEXIQUE
⁽⁴⁾ Hospital Psiquiatrico San Rafael, Mexico City, MEXIQUE
⁽⁵⁾ Investigation Department, Hospital Psiquiatrico Fray Bernardino Alvarez, Mexico City, MEXIQUE
⁽⁶⁾ Hospital Psiquiatrico Yucatan, Merida, Yucatan, MEXIQUE
⁽⁷⁾ Wyeth SA de CV, Mexico City, MEXIQUE

Résumé / Abstract

In this randomized, open-label, 8-week comparative study, the efficacy and safety of venlafaxine and fluoxetine were assessed in outpatients with major depression. One hundred forty-five patients were assigned to receive venlafaxine 37.5 mg twice daily or fluoxetine 20 mg once daily. On day 15, if clinically indicated to improve patient response, the dosage could be increased at the investigator's discretion to venlafaxine 75 mg twice daily or fluoxetine 40 mg once daily. One hundred forty-five patients were evaluated for safety and 110, for efficacy. The mean age was 37 years, and 70% of the patients were female. In both treatment groups, mean scores on the Hamilton Depression Rating Scale decreased significantly between baseline (27.8, venlafaxine; 29.2, fluoxetine) and the end of the study (8.7, venlafaxine; 8.2, fluoxetine). Similarly, mean scores on the Montgomery-Asberg Depression Rating Scale decreased significantly between baseline (31.4, venlafaxine ; 31.6, fluoxetine) and the end of the study (8.3, venlafaxine; 7.6, fluoxetine). In venlafaxine patients, the most common adverse events were nausea (44.3%), headache (40.0%), insomnia (31.4%), dizziness (30.0%), and dry mouth (22.9%); in fluoxetine patients, they were headache (32.0%), nausea (28.0%), insomnia (24.0%), anxiety (21.3%), sleepiness (20.0%), and generalized tremor (20.0%). The results of this study indicate that venlafaxine is effective and well tolerated for the treatment of major depression at doses of 37.5 or 75 mg twice daily and not significantly different from fluoxetine 20 or 40 mg once daily.

Revue / Journal Title

Clinical therapeutics   ISSN 0149-2918 

Source / Source

1998, vol. 20, n^o3, pp. 467-476 (25 ref.)

Langue / Language

Anglais

Editeur / Publisher

Excerpta Medica, Belle Mead, NJ, ETATS-UNIS  (1977) (Revue)

Mots-clés anglais / English Keywords

Fluoxetine ; Venlafaxine ; Antidepressant agent ; Psychotropic ; Depression ; Chemotherapy ; Treatment ; Ambulatory ; Human ; Reuptake inhibitor ; Serotonin ; Norepinephrine ; Treatment efficiency ; Toxicity ; Comparative study ; Dose activity relation ; Mood disorder ;

Mots-clés français / French Keywords

Fluoxétine ; Venlafaxine ; Antidépresseur ; Psychotrope ; Etat dépressif ; Chimiothérapie ; Traitement ; Ambulatoire ; Homme ; Inhibiteur recapture ; Sérotonine ; Noradrénaline ; Efficacité traitement ; Toxicité ; Etude comparative ; Relation dose réponse ; Trouble humeur ;

Mots-clés espagnols / Spanish Keywords

Fluoxetina ; Venlafaxina ; Antidepresor ; Psicotropo ; Estado depresivo ; Quimioterapia ; Tratamiento ; Ambulatorio ; Hombre ; Inhibidor recaptura ; Serotonina ; Noradrenalina ; Eficacia tratamiento ; Toxicidad ; Estudio comparativo ; Relación dosis respuesta ; Trastorno humor ;

Localisation / Location

INIST-CNRS, Cote INIST : 18353, 35400007241772.0080